Literature DB >> 30003319

[Novel molecular mechanisms in the pathophysiology of psoriatic arthritis].

D Simon1, E Kampylafka2, A J Hueber3.   

Abstract

The complex pathogenesis of psoriatic arthritis (PsA) is still only partially understood; however, recently a greatly improved understanding of this disease has been achieved, especially with respect to the inflammatory processes of the entheses. Thus, the clinical aspects of enthesitis increasingly differentiate PsA from other autoimmune diseases and sharpen the unique pathological clinical picture of PsA. Better pathophysiological understanding and the development of different biomarker approaches will bolster early detection of PsA. Therefore, the successful early recognition of PsA and more reliable identification of psoriasis patients at risk might be possible in the near future.

Entities:  

Keywords:  Biomarkers; Early recognition; Enthesitis; Pathogenesis; Risk patients

Mesh:

Substances:

Year:  2018        PMID: 30003319     DOI: 10.1007/s00393-018-0503-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  43 in total

1.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Quantitative and Qualitative Changes of Bone in Psoriasis and Psoriatic Arthritis Patients.

Authors:  Roland Kocijan; Matthias Englbrecht; Judith Haschka; David Simon; Arnd Kleyer; Stephanie Finzel; Sebastian Kraus; Heinrich Resch; Christian Muschitz; Klaus Engelke; Michael Sticherling; Jürgen Rech; Georg Schett
Journal:  J Bone Miner Res       Date:  2015-05-10       Impact factor: 6.741

3.  Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis.

Authors:  David Simon; Francesca Faustini; Arnd Kleyer; Judith Haschka; Matthias Englbrecht; Sebastian Kraus; Axel J Hueber; Roland Kocijan; Michael Sticherling; Georg Schett; Jürgen Rech
Journal:  Ann Rheum Dis       Date:  2015-02-04       Impact factor: 19.103

4.  Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis.

Authors:  Richard J Cuthbert; Evangelos M Fragkakis; Robert Dunsmuir; Zhi Li; Mark Coles; Helena Marzo-Ortega; Peter V Giannoudis; Elena Jones; Yasser M El-Sherbiny; Dennis McGonagle
Journal:  Arthritis Rheumatol       Date:  2017-08-08       Impact factor: 10.995

5.  Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?

Authors:  G-M Alenius; C Eriksson; S Rantapää Dahlqvist
Journal:  Clin Exp Rheumatol       Date:  2009 Jan-Feb       Impact factor: 4.473

6.  Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.

Authors:  C Johansen; P A Usher; R B Kjellerup; D Lundsgaard; L Iversen; K Kragballe
Journal:  Br J Dermatol       Date:  2008-10-21       Impact factor: 9.302

Review 7.  Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions.

Authors:  Ananta Paine; Christopher Ritchlin
Journal:  Calcif Tissue Int       Date:  2018-01-12       Impact factor: 4.333

8.  S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis.

Authors:  Claes Hansson; Catharina Eriksson; Gerd-Marie Alenius
Journal:  J Immunol Res       Date:  2014-05-14       Impact factor: 4.818

9.  Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis.

Authors:  Nikolai Dyrberg Loft; Lone Skov; Mads Kirchheiner Rasmussen; Robert Gniadecki; Tomas Norman Dam; Ivan Brandslund; Hans Jürgen Hoffmann; Malene Rohr Andersen; Ram Benny Dessau; Ann Christina Bergmann; Niels Møller Andersen; Mikkel Kramme Abildtoft; Paal Skytt Andersen; Merete Lund Hetland; Bente Glintborg; Steffen Bank; Ulla Vogel; Vibeke Andersen
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

10.  Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).

Authors:  Peter Nash; Kamal Ohson; Jessica Walsh; Nikolay Delev; Dianne Nguyen; Lichen Teng; Juan J Gómez-Reino; Jacob A Aelion
Journal:  Ann Rheum Dis       Date:  2018-01-17       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.